FABLESS BIOLOGICS &
VACCINE MANUFACTURING
Producing affordable pharmaceuticals through global innovation and Canadian infrastructure.
Get in TouchOUR MISSION
To produce affordable pharmaceuticals by licensing global innovations and utilizing Canadian biomanufacturing infrastructure.
Affordability
We aim to challenge the dominance of US "Big Pharma" by reducing the burden of high cost vaccines & biologics on the Canadian taxpayer through leveraging domestic manufacturing capabilities.
Our Vision
Become Canada's first agile, cost-efficient bridge for licensing, developing, and commercializing innovative foreign intellectual property in large molecule pharmaceuticals.
Canada was once a leader in public vaccine manufacturing
In 1914, Connaught Labs produced antitoxins as a public, not-for-profit institute tied to the University of Toronto.
But by the 1990s, privatization and foreign acquisitions (Connaught → Sanofi, Armand Frappier → GSK) dismantled our domestic capacity, leaving Canada exposed during COVID 19.
In response, the federal government invested $126 million in the Biologics Manufacturing Centre (BMC) — which today remains underutilized, with only one confirmed partner.
Cost
High out-of-pocket costs
Cost
Even with public and private coverage, patients still pay high out-of-pocket costs—while taxpayers foot inflated bills driven by pharma pricing power.
Fragile Health Sovereignty
Reliance on foreign giants
Fragile Health Sovereignty
Canada relies on foreign pharma giants, with little control over supply, pricing, or production.
Vulnerable Supply Chains
Exposed inability to produce
Vulnerable Supply Chains
Pandemics and geopolitics have exposed our inability to produce critical medicines when it matters most.
Innovation Bottleneck
Delayed therapies
Innovation Bottleneck
Cutting-edge therapies abroad are delayed or unavailable in Canada due to lack of domestic licensing and trial pathways.
Rebuild Domestic Biotech
Resilient domestic pipeline
Rebuild Domestic Biotech
License late-phase global innovations and invest in Canadian-led development and commercialization, building a resilient domestic pipeline.
Deploy Idle Capacity
Untapped national capacity
Deploy Idle Capacity
Facilities like the Biologics Manufacturing Centre (BMC) represent untapped national capacity.
Slash Costs
Affordable biologics
Slash Costs
Avoid traditional R&D overhead and global distribution markups to offer affordable, locally made biologics for both patients and healthcare systems.
Eliminate Price Gouging
Minimize excessive markups
Eliminate Price Gouging
Minimizing cost allows minimizing excessive markups to patients while still offering high-quality medicines.
“If drug development is supported by taxpayer dollars, then the public deserves access to its rewards—not just private shareholders.”
We believe that public funding should yield public returns.
We believe in a resilient, self-sufficient Canadian pharmaceutical system, free of foreign interference, ready for pandemics and supply chain shocks.